Khalid Shumburo, MD
Nephrology · Fairfax, VANPI 1952379737
Payments from drug & device makers
Across 37 payments — averaging $102.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exthera Medical Corporation$3K
- Mallinckrodt Hospital Products Inc.$173
- Amgen$162
- Fresenius USA Marketing, Inc.$121
- Bard Peripheral Vascular, Inc.$108
- Akebia Therapeutics Inc$94
- plus $350 from 11 others
What the payments were for
- Food & beverage$90890%
- Education$10010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exthera Medical Corporation | 2 | $2,777 |
| Mallinckrodt Hospital Products Inc. | 4 | $173 |
| Amgen(2 entities) | 7 | $162 |
| Fresenius USA Marketing, Inc. | 5 | $121 |
| Bard Peripheral Vascular, Inc. | 1 | $108 |
| Akebia Therapeutics Inc | 1 | $94 |
| Vifor Pharma, Inc. | 4 | $87 |
| Mallinckrodt Enterprises LLC | 3 | $56 |
| Novartis | 2 | $37 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Travere Therapeutics, Inc. | 1 | $26 |
| Recor Medical Inc | 1 | $22 |
| GSK | 1 | $22 |
| Calliditas Therapeutics US Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| OPKO Pharmaceuticals, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
How this compares
$3,784 in reported general payments places this provider in the 70th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 101 | $26,627 |
| Sevelamer Carbonate | 25 | $3,385 |
| Clonidine | 20 | $3,223 |
| Potassium Citrate ErPotassium Citrate | 21 | $2,071 |
| Tacrolimus | 18 | $1,778 |
| Metoprolol Succinate | 68 | $1,117 |
| Doxazosin Mesylate | 39 | $1,029 |
| Losartan Potassium | 91 | $902 |
| Hydralazine Hcl | 65 | $666 |
| Calcium Acetate | 25 | $659 |
| Torsemide | 54 | $639 |
| Amlodipine Besylate | 95 | $477 |
| Bumetanide | 12 | $459 |
| Rosuvastatin Calcium | 12 | $431 |
| Midodrine Hcl | 12 | $421 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fairfax
- Ahmadshah MirkhelFairfax$902K
- Renuka SothinathanFairfax$617K
- Reza ZonoziFairfax$482K
- Ali AssefiFairfax$302K
- Kinjal PatelFairfax$31K
- Gregory WangFairfax$30K
- Renu Regunathan-ShenkFairfax$22K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Olayiwola AyodejiHampton$7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.